+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review

F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd Key Recent Developments

Oct 19,2023: Roche Reports Good Sales Growth Despite Decline in Demand for COVID-19 Products
Sep 19,2023: Baxter Planning''s predictive Service Supply Chain platform chosen by Roche Diagnostics Corporation for Service Supply Chain Optimization
Aug 08,2023: New Opportunities and Persistent Challenges Revealed as Organisations Attempt More Data-Driven Approaches to Healthcare, Says New Report From Harvard Business Review Analytic Services
Jul 27,2023: F. Hoffmann-La Roche Announces Half Year Results 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • F. Hoffmann-La Roche Ltd - Key Facts
  • F. Hoffmann-La Roche Ltd - Key Employees
  • F. Hoffmann-La Roche Ltd - Key Employee Biographies
  • F. Hoffmann-La Roche Ltd - Major Products and Services
  • F. Hoffmann-La Roche Ltd - History
  • F. Hoffmann-La Roche Ltd - Company Statement
  • F. Hoffmann-La Roche Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
Section 2 - Company Analysis
  • Company Overview
  • F. Hoffmann-La Roche Ltd - Business Description
  • Business Segment: Diagnostics
  • Overview
  • Performance
  • Business Segment: Pharmaceuticals
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Africa, Australia and Oceania
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • F. Hoffmann-La Roche Ltd - Corporate Strategy
  • F. Hoffmann-La Roche Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • F. Hoffmann-La Roche Ltd - Strengths
  • F. Hoffmann-La Roche Ltd - Weaknesses
  • F. Hoffmann-La Roche Ltd - Opportunities
  • F. Hoffmann-La Roche Ltd - Threats
  • F. Hoffmann-La Roche Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • F. Hoffmann-La Roche Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Oct 19, 2023: Roche Reports Good Sales Growth Despite Decline in Demand for COVID-19 Products
  • Sep 19, 2023: Baxter Planning''s predictive Service Supply Chain platform chosen by Roche Diagnostics Corporation for Service Supply Chain Optimization
  • Aug 08, 2023: New Opportunities and Persistent Challenges Revealed as Organisations Attempt More Data-Driven Approaches to Healthcare, Says New Report From Harvard Business Review Analytic Services
  • Jul 27, 2023: F. Hoffmann-La Roche Announces Half Year Results 2023
  • Jul 26, 2023: Roche Reports Strong Growth in Both Divisions’ Base Business; Group Sales and Profit Reflect Declining Demand for COVID-19 Products
  • Jul 24, 2023: Roche and Alnylam partner for RNAi therapeutic development
  • Jun 01, 2023: New Coalition Launched to Fight Breast and Cervical Cancers Across Asia-Pacific
  • May 26, 2023: Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
  • May 24, 2023: Jnana Therapeutics announces milestone achieved under first collaboration with Roche
  • May 04, 2023: Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • F. Hoffmann-La Roche Ltd, Key Facts
  • F. Hoffmann-La Roche Ltd, Key Employees
  • F. Hoffmann-La Roche Ltd, Key Employee Biographies
  • F. Hoffmann-La Roche Ltd, Major Products and Services
  • F. Hoffmann-La Roche Ltd, History
  • F. Hoffmann-La Roche Ltd, Subsidiaries
  • F. Hoffmann-La Roche Ltd, Affiliate
  • F. Hoffmann-La Roche Ltd, Key Competitors
  • F. Hoffmann-La Roche Ltd, Ratios based on current share price
  • F. Hoffmann-La Roche Ltd, Annual Ratios
  • F. Hoffmann-La Roche Ltd, Annual Ratios (Cont...1)
  • F. Hoffmann-La Roche Ltd, Annual Ratios (Cont...2)
  • F. Hoffmann-La Roche Ltd, Interim Ratios
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • F. Hoffmann-La Roche Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • F. Hoffmann-La Roche Ltd, Performance Chart (2018 - 2022)
  • F. Hoffmann-La Roche Ltd, Ratio Charts
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck & Co Inc
  • Johnson & Johnson
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Amgen Inc
  • AbbVie Inc
  • Pfizer Inc
  • Bristol-Myers Squibb Co
  • Abbott Laboratories
  • Takeda Pharmaceutical Co Ltd
  • Spexis AG
  • Novartis AG
  • Bio-Rad Laboratories Inc
  • Incyte Corp
  • Sanofi
  • Cassava Sciences Inc
  • Bayer AG
  • Viridian Therapeutics Inc
  • Kuros Biosciences AG
  • GSK plc
  • Eli Lilly and Co
  • Sanofi
  • Bayer AG
  • Abbott Laboratories
  • Eli Lilly and Co
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Ra Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Incyte Corp
  • Viridian Therapeutics Inc
  • Kuros Biosciences AG
  • GSK plc
  • Johnson & Johnson
  • Amgen Inc
  • AbbVie Inc
  • Pfizer Inc
  • Spexis AG
  • Novartis AG
  • Bio-Rad Laboratories Inc
  • Cassava Sciences Inc
  • Takeda Pharmaceutical Co Ltd
  • Merck & Co Inc